AtaCor Medical announced that it completed enrollment in its initial acute extravascular implantable cardioverter defibrillator (EV-ICD) study.
San Clemente, California-based AtaCor’s PASS-PULL EV-ICD study will evaluate the company’s EV-ICD lead in connection with commercially available ICDs.
According to a news release, AtaCor designed its novel EV-ICD to provide both shock and anti-tachycardia pacing therapies to treat life-threatening tachyarrhythmias and pacing therapies to treat bradycardia with aims to reducing dependency on transvenous ICD leads and the complications associated with them.
The AtaCor custom delivery tool aids in the insertion of the lead through a rib space at the left sternal margin above the heart. The final lead position is adjacent to the sternum, leaving the heart completely untouched.
PASS-PULL EV-ICD will evaluate the delivery of AtaCor’s EV-ICD lead and its acute defibrillation success. The study enrolled 12 patients and underwent testing, with results set to be submitted for peer-review analysis and publication.
“While AtaCor continues to develop novel solutions for extravascular pacing, we are excited to complete our first defibrillation study,” AtaCor CEO Rick Sanghera said in the release. “Our goal is to revolutionize the entire cardiac rhythm management industry, and this study highlights that effort.”